Print this page Basel, Switzerland, February 13, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader… Read More »
ANOTHER Alzheimer’s drug fails: Trials of a highly-anticipated experimental treatment cancelled two years early Drugmaker Roche has cancelled two clinical trials of an experimental Alzheimer’s drug, crenezumab The pair of trials join over 100 failed Alzheimer’s trials Crenezumab was thought to target harmful protein plaques in the brains of early-stage dementia sufferers But the patients’… Read More »
A study has found that acupressure could be a low-cost, DIY solution for a set of persistent side effects which remain after conventional treatment for breast cancer is completed. It was reported by researchers in 2016 that acupressure helped with a reduction of fatigue in breast cancer survivors. This current study examined how acupressure impacted… Read More »
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). SAGE-547, now called brexanolone, is a neurosteroid, an analogue of allopregnanolone and an allosteric modulator of GABAA receptors. Since that time, Sage Therapeutics has conducted three randomized controlled trials, enrolling a total of 247 women diagnosed… Read More »